Jushi Holdings (JUSHF) Other Non-Current Liabilities (2021 - 2026)
Jushi Holdings (JUSHF) posted quarterly Other Non-Current Liabilities of $193.9 million for Q2 2026, up 19.14% year-over-year from $162.8 million in Q2 2025, and up 4.14% quarter-over-quarter from $186.2 million in Q1 2026.
Jushi Holdings (JUSHF) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has reported Other Non-Current Liabilities for 6 consecutive years, with $193.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 19.14% year-over-year to $193.9 million; the TTM figure through Jun 2026 stood at $193.9 million (up 19.14% YoY), while the FY2025 annual figure was $177.2 million, up 23.35% from the prior year.
- Other Non-Current Liabilities grew to $193.9 million in Q2 2026 per JUSHF's latest filing, from $186.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $193.9 million in Q2 2026 and bottomed at $14.1 million in Q4 2022.
- Historically, Other Non-Current Liabilities has averaged $116.3 million across 5 years, with a median of $118.2 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 84.71% — and 2023, when it soared 640.24%.
- Jushi Holdings' Other Non-Current Liabilities stood at $14.1 million in 2022, then jumped by 640.24% to $104.6 million in 2023, then soared by 37.34% to $143.7 million in 2024, then rose by 23.35% to $177.2 million in 2025, then gained by 9.42% to $193.9 million in 2026.
- Business Quant data shows JUSHF's Other Non-Current Liabilities at $193.9 million in Q2 2026, $186.2 million in Q1 2026, and $177.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Jushi Holdings | 83.87 Mn | 50.54 Mn | 31.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 193.95 Mn |
| Mar 31, 2026 | 186.23 Mn |
| Dec 31, 2025 | 177.24 Mn |
| Sep 30, 2025 | 171.18 Mn |
| Jun 30, 2025 | 162.79 Mn |
| Mar 31, 2025 | 153.05 Mn |
| Dec 31, 2024 | 143.69 Mn |
| Sep 30, 2024 | 136.09 Mn |
| Jun 30, 2024 | 127.14 Mn |
| Mar 31, 2024 | 109.20 Mn |
| Dec 31, 2023 | 104.63 Mn |
| Sep 30, 2023 | 98.95 Mn |
| Jun 30, 2023 | 60.49 Mn |
| Mar 31, 2023 | 59.10 Mn |
| Dec 31, 2022 | 14.13 Mn |
| Sep 30, 2022 | 62.40 Mn |
| Jun 30, 2022 | 71.10 Mn |
| Mar 31, 2022 | 61.28 Mn |
| Dec 31, 2021 | 92.44 Mn |